### COVER STORY: TARGETS & MECHANISMS

## Science-Business eXchange

# The 'smoking gun' in ALS

By Lev Osherovich, Senior Writer

A spate of reports buttresses the case for TDP-43 as a key player in amyotrophic lateral sclerosis. But even though the protein is mislocalized in a majority of patients, drug developers are holding off on targeting TDP-43 until more is known about its function. Instead, most companies are sticking with better-studied targets such as neuronal receptors and another mutated protein, superoxide dismutase 1.

Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder that causes loss of sensation, motor difficulties and paralysis. ALS is usually sporadic, but a small number of cases have previously been linked to hereditary mutations in superoxide dismutase 1 (SOD1).

SOD1's normal function is to lower superoxide radicals inside of cells, but SOD1-linked ALS does not merely result from loss of normal SOD1 activity. In familial ALS patients, SOD1 forms toxic intracellular aggregates, although the mechanism by which this leads to clinical disease is poorly understood.

Only one drug, Rilutek riluzone from **sanofi-aventis Group**, is approved for ALS. It extends survival and time to tracheostomy by reducing glutamate neurotransmitter levels, but lifespan is extended only a few months.<sup>1</sup>

Rilutek, as well as neurotrophic factor therapeutics in various stages of development, boost neuronal health but are not thought to directly affect protein aggregation (*see* **Table 1**, "**Amyotrophic lateral sclerosis pipeline**").

Now, a study published in *Science* by an international team led by Christopher Shaw of **King's College London** describes hereditary and sporadic mutations in human TDP-43 that also cause ALS.<sup>2</sup> The gene-mapping study involved five individuals from the same family. The researchers validated their results by finding TDP-43 mutations in 3 unrelated sporadic ALS patients out of a 526-patient cohort. Like SOD1, TDP-43 forms aggregates in the neurons of ALS patients.

In a concurrent *Journal of Biological Chemistry* paper, a group led by Virginia Lee, professor of pathology and lab medicine at the **University of Pennsylvania School of Medicine**, reported a new cell culture model for TDP-43 pathology.<sup>3</sup> The team found that engineered versions of TDP-43 missing the nuclear localization sequence mislocalize to the cytoplasm and form ubiquitinated aggregates, a hallmark of ALS pathology.

Shaw said his group's findings lay to rest the question of whether TDP-43 is a culprit or bystander in the disease.

The publication is "the smoking gun that validates the pathology" of TDP-43 in ALS, according to Lee, whose group first reported the presence of abnormally localized TDP-43 in the brains of ALS patients in 2006.<sup>4</sup>

"TDP-43 had already been identified in ALS, but it was thought that it was a piece of cellular junk, not the cause of disease," Shaw told *SciBX*. His team identified three separate mutations that were sufficient to cause ALS, and they went on to show in a chick embryo model of neural development that mutant forms of the protein can cause pathology. Shaw said the study is "the first mechanistic link" between TDP-43 and ALS.

It thus appears that both SOD1 and TDP-43 form toxic protein aggregates in the cytoplasm, although it's still unknown whether these problems are related or how they ultimately lead to motor neuron damage.

A hint at the downstream events in ALS comes from a new study of neuropathology caused by expressing mutant SOD1 in mice. The report in *Nature Neuroscience* shows the accumulation of antibodies and other serum proteins around damaged neurons, suggesting a breakdown of the barrier between the blood and the nervous system.<sup>5</sup> The work was conducted by a **University of Rochester Medical Center** team lead by Berislav Zlokovic.

Jeff Rothstein, professor of neurology at **Johns Hopkins University**, told *SciBX* that researchers are divided about which of the two proteins is more important in sporadic ALS, which is considerably more common than the SOD1- or TDP-43-linked derivations of the disease. "The SOD1 side of the world thinks that SOD1 aggregation could account for sporadic ALS" in addition to the hereditary form, said Rothstein. "Now the TDP-43 camp has a stronger case."

The aforementioned reports, along with another genetic study published in the *Annals of Neurology* that shows an additional hereditary TDP-43 mutation is linked with ALS,<sup>6</sup> could cause a paradigm shift in research, according to Lee.

Many therapeutics in development target SOD1 or SOD1-related biochemical pathways, which may underpin only a minority of ALS cases, said Shaw. A change of focus to TDP-43 would be more productive, he explained, because "95% of all people with ALS have TDP-43 aggregates, but we've been trying to treat a SOD1 model."

Industry researchers, however, want a bit more data before they change direction. Frank Bennett, SVP of research at **Isis Pharmaceuticals Inc.**, said Shaw's paper was an important step forward, but he thinks it is "still an open question" whether TDP-43 is a good drug target. The company's ISIS 333611, an antisense inhibitor of SOD1 expression, is in preclinical development for ALS.

Bennett told *SciBX* that knocking down SOD1 might still be useful in treating sporadic ALS, which could potentially arise from problems with TDP-43 or other proteins that may ultimately influence SOD1 activity.

"It's nice to finally see the purely correlative observations relating TDP-43 inclusions to ALS confirmed through genetic linkage analysis," said Chris Wigley, VP of research at **Reata Pharmaceuticals Inc.** Wigley said Reata still will focus its ALS efforts on small molecules that

## **COVER STORY**

CompanyProductDescriptionStart Phase IIIAvicena Group Inc. (OTCBB:AVGO)AL-02Formulation of creatineStart Phase IIIMitsubishi Tanabe Pharma Corp. (Tokyo-5056). Coska:4508)Edavarone (MCI-186)Free radical scavengerPhase IIIOrtokyo-5056). Coska:4508)ArimoclomolHydroxylamine derivative that induces heat shock protein expressionPhase IIIFaust Pharmaceuticals S.A.FP0011Orally available small-molecule glutamate inhibitorPhase IITeva Pharmaceuticals S.A.FP0011Orally available small-molecule glutamate inhibitorPhase IIOno Pharmaceuticals S.A.FP0011Orally available small-molecule glutamate inhibitorPhase IITeva Pharmaceuticals Co. Ltd.Cereact capsule (ONO-2506PO)Astrocyte modulatorPhase IITeva Pharmaceutical Industries Ltd.TallampanelSelective major histocompatibility complex (MHC) class II modulatorPhase IITeva Pharmaceutical Inc.TKE-201Sodium phenylbutyratePhase II in 2008AvicenaAl-08 plus celecoxibFormulation of creatine plus celecoxibSart Phase II in 2008AvicenaKNS-760704Optical enantiomer of dopamine agonist pramipexolePhase I Phase I Phase II in 2008Avogen Inc. (TSX:VAS; NASDAQ:VSCN)VP025Atalytic antioxidantPhase I Phase II Phase II in 2008Vasogen Inc. (TSX:VAS; NASDAQ:VSCN)VP025Atalytic antioxidant permessibility transition pore with the mitochondrial permessibility transition pore with the mitochondrial permessibility transition porePhase I <br< th=""><th></th><th>Developed</th><th></th><th>01-1-1-</th></br<>		Developed		01-1-1-
Avicena Group Inc. (OTCB8:AVGO)AI-02Formulation of creatineStart Phase III Sitt Phase III Sitt Sitt Sitt Sitt Sitt Sitt Sitt Sitt	Company	Product	Description	Status
Mitsibi Tanabe Phane Gorp. (Tokyot508; Osaka:1508)Edavarone (MCI-186)Free radical scavengerPhase IIICytRx Corp. (NASDAQ:CYTR)ArinoclomolPhytorylamine derivative that induces heat shock protein expressionPhose IIIFaust Pharmaceuticals So. LALFP011Orally variable small-molecule glutamate inhibitorPhase IIIOno Pharmaceuticals Co.LALCereact capsule (NO-2506PO)Aricocyte modulatorPhase IIITeva Pharmaceutical Industries LtAL (NASDAQ:TEVA)Copasone glatirame acetaeSelective major histocompatibility complex (MHC) class III modulatorPhase IIITeva AlexanderTK-201Solimo phenylutyratePhase IIIAvicenaTK-201Solimo foreatine plus celecoxib modulatorPhase III in 2008AvicenaSt-509Selostive major histocompatibility complex (MHC) class III modulatorPhase III in 2008AvicenaTK-201Solimo foreatine plus celecoxibPhase III in 2008AvicenaTK-500Selostive major histocompatibility complex (MHC) class III in 2008Phase III in 2008AvicenaTK-201Solimo foreatine plus celecoxibPhase III in 2008AvicenaTK-500Selostive major histocompatibility complex (MHC) class III in 2008Phase III in 2008AvicenaTK-500Selostive major histocompatibility complex (MHC) class III in 2008Phase III in 2008AvicenaTK-500Selostive major histocompatibility complex (MHC) class III in 2008Phase III in 2008AvicenaTK-500Selostive major histocompati	Avicena Group Inc. (OTCBB:AVGO)	AL-02	Formulation of creatine	Start Phase III in 2H08
Qrkx Corp. (NASDAQ:CYTR)ArimoclonolHydrophamic derivative that induces heat shock proteinPhase Ib^Faust Pharmaceuticals S.A.FP011Oraly available small-molecule glutamate inhibtorPhase IaOno Pharmaceuticals Co. Lid. (Nox-526 OSA)Grecat capsule (Nox-526 OSA)Arkorcyte modulatorPhase IaTeva Pharmaceutical Industries Lid.TalampanelAPA receptor blockerPhase IaTeva Pharmaceutical Industries Lid.TiK-201Solum phnylbutyratePhase IaTikvah Therapeutics Inc.TiK-201Solum phnylbutyratePhase IaAricenaAl-08 plus celeccishFormulation of creatine plus celecoxibStar Phase IaSolus Disolecteres Inc. (NASDAQ:SGW)So-509Calculation of creatine plus celecoxibStar Phase IaAnganese plusAl-08 plus celeccishCalculation of Creatine plus celecoxibStar Phase IaSolus Disolecteres Inc. (NASDAQ:SGW)So-509Calculation of Creatine plus celecoxibStar Phase IaAnganese plusAl-08 plus celecoxibCalculation of Al-02 plusPhase IaSolus Disolecteres Inc. (NASDAQ:SGW)RosonoPhase IaPhase IaAl-09 plus CalculationNaganese plusNaganese plusPhase IaSolus Disolecteres Inc. (NASDAQ:SGW)NoganePhase IaPhase IaSolus Disolecteres Inc. (NASDAQ:SGW)Phose IaPhase IaPhase IaSolus Disolecteres Inc. (NASDAQ:SGW)Phose IaPhase IaPhase IaSolus Disolecteres Inc. (NASDAQ:SGW)Phose IaPhase IaPhase IaSolus Di	Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508)	Edavarone (MCI-186)	Free radical scavenger	Phase III
Faust Pharmaceuticals S.A.FP0011Orally available small-molecule glutamate inhibitorPhase IIOno Pharmaceuticals Co. Lid.Cercat capsule (NON-2500PC)Arcroyte modulatorPhase IITickayo 4528; Osaka-4529TampanelAMPA receptor blockerPhase IITeva Pharmaceutical Industries Lud.Tick-201Selective major histocompatibility complex (MHC) class IIPhase IITikvah Therapeutics Inc.TIK-201Sodium phenylbutyratePhase IIAvicenaL.N.8 plus celecoxibFornulation of creatine plus celecoxibSart Phase IIAvicenaMaganese porphyrinCatalytic antioxidantSart Phase IIAcous Pharmaceuticals Inc. (NASDAQ:SGMO)B-509Catalytic antioxidantPhase IAcous Pharmaceuticals Inc. (NASDAQ:SGMO)Naganese porphyrinCatalytic antioxidantPhase INorphyrine Pict SE:PYMMoganeSart Phase IINaganesePhytopharm pict (SE:PYM)NorgaSmall molecule with cholesterol-fike structure that interactsPhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGMO)VD25Anti-inflamatory compound that modulates cytokine levelPhase ISubsidiary of CytRx Corp.Catefing RNASelon-associated virus vectors carrying insuli-file groupPredinicalSubsidiary of CytRx Corp.NIST-194Selon-associated virus periodie dismutates (SODI)PredinicalSubsidiary of CytRx Corp.NIST-194Selon-associated virus periodie dismutates (SODI)PredinicalSubsidiary of CytRx Corp.Sitting RNASelon-associated virus periodie dismutates (SODI)Predin	CytRx Corp. (NASDAQ:CYTR)	Arimoclomol	Hydroxylamine derivative that induces heat shock protein expression	Phase IIb <sup>A</sup>
One Pharmaceuticals O.S. L.S. (NON-23060)Airscy envolutionPhase IITeva Pharmaceutical Industries LideIamanalAPA receptor blockerPhase IITevaOragone galaremSective major blockor publicity complex (MHC) class IIPhase IIITikva Therapeutics Inc.MC 10Sective major blockor publicity complex (MHC) class IIPhase IIIAirchanTevaSective major blockor publicity complex (MHC) class IIIPhase IIIAirchanML 201Sective major blockor publicity complex (MHC) class IIIPhase IIIAirchanML 201Sective major blockor publicity complex (MHC) class IIIPhase IIIAirchanML 201Sective major blockor publicity complex (MHC) class IIIPhase IIIAirchanML 201Sective major blockor publicity complex (MHC) class IIIPhase IIIAirchanML 201Sective major blockor publicity complex (MHC) class IIIPhase IIIAirchanMagnee complexPhase IIIIPhase IIIIAirchanMagnee complexSective major blockor publicity class IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	Faust Pharmaceuticals S.A.	FP0011	Orally available small-molecule glutamate inhibitor	Phase II
Teva Pharmaceutical Industries Ltd. (XASDAQ:TEVA)TalampanlAMPA receptor blockerPhase IITevaCopaxone glariame acctateSelective major histocompatibily complex (MHC) class IIPhase IITikvah Therapeutics Inc.TIK-201Solum phenylbutyratePhase IIAvicenaL-08 plus celccoxibFornulation of creatine plus celecoxibSart Phase IISangano BioSciences Inc. (NASDAQ:SGMO)Bs-509Tanscriptional activator of VEGF-ASart Phase IIAolus Pharmaceutical Inc. (OTCBB:AOL)Maganes porphyriCalulational control of opamine agonits pramipexolePhase IPhytopharmaple (LSE:PYM)KNS-76074Optical enationer of dopamine agonits pramipexolePhase IPhytopharm plc (LSE:PYM)NoganeNonpetide neurotrophic factor inducerPhase IPhytopharm plc (LSE:PYM)PO25Anti-inflammatory compound that modulate cytokinelymesePhase ISuspen FuncRCB-130Salcionalizi permetability transition programPhase ISubidiary of Cytick Corp.NorgenNordenesen anti-inflammatory compound that modulate cytokinelymesePhase ISubidiary of Cytick Corp.Silc Sala10Scongenaria antisens inhibitor of SOD1PiclinicalSubidiary of Cytick Corp.Nor2495Nor2495Naclaregenation englise inhibitor of SOD1PiclinicalNeuroNova ABNova240Nova240VEGFportinPiclinicalSubidiary of Cytick Corp.Nova240VEGFportinPiclinicalNeuroNova ABStoloStoloPiclinicalSupisharmaceuticals Inc.Sto	Ono Pharmaceuticals Co. Ltd. (Tokyo:4528; Osaka:4528)	Cereact capsule (ONO-2506PO)	Astrocyte modulator	Phase II
TevaCopason glatiram createSelective major histocompatibility complex (MHC) class IIIPlans IIITikvah Therapeutics Inc.TIK-201Sodum penylbuyrateMear IAvienaAn9 plus cleccoxibFrankaion for creatine plus cleccoxibRip Plans RipSagamo BioSciences Inc. (NASDAQ-SGMO)Sb59Takscriptional activator of VEGF-ARip Plans RipAnop Neurosciences Inc.KNS-700704Otical cantonic of dopamine agoint pramipeosoMear IPhytopharmetric ISE-PYMKNS-700704Otical cantonic of dopamine agoint pramipeosoMear IPhytopharmetric SE-PYMKNS-700704Nopeptide neurotrophic factor inducerMear IPhytopharmetric ISE-PYMKNS-700704Nopeptide neurotrophic factor inducerMear ISologen Inc. (TSX-VAS, NASDAQ-VSGM)Plo25Anti-inflamatory compound that modulates cytokine ploaPloaficalSubisdiary of Cytopharmetric Ise SubsciencesSingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloaficalSubsciences Inc.SingersonSingersonPloafic	Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)	Talampanel	AMPA receptor blocker	Phase II
Tikvah Therapeutics Inc.TIK-201Sodium phenylbutyratePhase IIAivenaAl-08 plus celecoxibFormulation of creatine plus celecoxibSlart Phase II in 2008Snagamo BioSciences Inc. (NASDAQ:SGM)Bs-509Transcriptional activator of VEGF-ASlart Phase II in 2008Aclous Pharmaceuticals Inc. (OTCBB:AOLS)Maganese porphyrin (AEOL 10150)Caldytic antioxidantPhase INopp Neurosciences Inc.KNS-760704Optical enautomer of dopamine agonist pramipexolePhase IPhytopharm plc (LSE:PYM)MoganeNonpeptide neurotrophic factor inducerPhase ITorphos S.A.TRO19622Snall molecule with cholesterol-like structure that interactors with the micchondrial permeability transition por Michen Charles Partices Inc.Phase ICaregen Inc.VE055Anti-inflamatory compound that modulates cytokine levels afcor-1Phaer ISubsidiary of CytRx Corp.Interfering RNA 	Teva	Copaxone glatiramer acetate	Selective major histocompatibility complex (MHC) class II modulator	Phase II <sup>B</sup>
AvienaAl-08 plus celecoxibFormulation of creatine plus celecoxibSart Phase II in 2008Sangamo BioSciences Inc. (NASDAQ:SGMO)8-509Tanscriptional activator of VEGF-ASart Phase II in 2008Acolus Pharmaceuticals Inc. (OTCBB:AOLS)Maganese porphyrin Kopp Neurosciences Inc.KNS-760704Catalytic antioxidantPhase IPhytopharm plc (LSE:PYM)MoganeNopeptide neurotrophic factor inducerPhase ITorphos S.A.TRO19622Sall molecule with cholesterol-like structure that interactors 	Tikvah Therapeutics Inc.	TIK-201	Sodium phenylbutyrate	Phase II
Sangamo BioSciences Inc. (NASDAQ:SGMO)SB-509Transcriptional activator of VEGF-AStart Phase II in 2008Acolus Pharmaceuticals Inc. (OTCBB:AOLS)Maganese porphyrin (AEOL 10150)Catalytic antioxidantPhase IKnopp Neurosciences Inc.KNS-760704Optical enantiomer of dopamine agonist pramipexolePhase IPhytopharm plc (LSE:PYM)MoganeNonpeptide neurotrophic factor inducerPhase ITorphos S.A.TRO19622Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition poroPhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Caton-associance virus vectors carrying insulin-like growth actor-1PreclinicalSubsidiary of CytRx Corp.ISIS 33611Scond-generation antisense inhibitor of SOD1PreclinicalNeuron Pharmaceuticals Ltd. (ASX:NEU) Metabolic Pharmaceuticals Inc. (MASDAQ: MSIH)NN029VEGF proteinPreclinicalNeuron Nova ABNN029VEGF proteinPreclinicalPreclinicalSuppis Pharma AG (FSE:LIO)At200G-CSFPreclinicalPreclinical	Avicena	AL-08 plus celecoxib	Formulation of creatine plus celecoxib	Start Phase II in 2008
Aeolus Pharmaceuticals Inc. (OTCBB:AOLS)Manganese porphyrin (AEOL 10150)Catalytic antioxidantPhase IKnopp Neurosciences Inc.KNS-760704Optical enantiomer of dopamine agonist pramipexolePhase IPhytopharm plc (LSE:PYM)MoganeNonpeptide neurotrophic factor inducerPhase ITorphos S.A.TRO19622Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition porePhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth factor-1PreclinicalSubsidiary of CytRx Corp.Interfering RNA 	Sangamo BioSciences Inc. (NASDAQ:SGMO)	SB-509	Transcriptional activator of VEGF-A	Start Phase II in 2008
Knopp Neurosciences Inc.KNS-760704Optical enantiomer of dopamine agonist pramipexolePhase IPhytopharm plc (LSE:PYM)MoganeNonpeptide neurotrophic factor inducerPhase ITrophos S.A.RR019622Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition porePhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth factor-1PreclinicalRXi Pharmaceuticals Corp. (NASDAQ:RXII)Interfering RNA compoundSecond-generation antisense inhibitor of SOD1PreclinicalNeuro Pharmaceuticals Ltd. (ASX:NEU)/ 	Aeolus Pharmaceuticals Inc. (OTCBB:AOLS)	Manganese porphyrin (AEOL 10150)	Catalytic antioxidant	Phase I
Phytopharm plc (LSE:PYM)MyoganeNonpeptide neurotrophic factor inducerPhase ITrophos S.A.TRO19622Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition porePhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth ractor-1PreclinicalRXi Pharmaceuticals Corp. (NASDAQ:RXII)Interfering RNA compoundSecond-generation antisense inhibitor of SOD1PreclinicalIsis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 333611Second-generation peptidePreclinicalNeuron Pharmaceuticals Ltd. (ASX:NEU/) 	Knopp Neurosciences Inc.	KNS-760704	Optical enantiomer of dopamine agonist pramipexole	Phase I
Trophos S.A.TRO19622Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition porePhase IVasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth factor-1PreclinicalRXi Pharmaceuticals Corp. (NASDAQ:RXII), subsidiary of CytRx Corp.Interfering RNA compoundRNAi compound inhibiting superoxide dismutase (SOD1)PreclinicalIsis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 333611Second-generation antisense inhibitor of SOD1PreclinicalNeuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABSNN029VEGF proteinPreclinicalPreclinicalReata Pharmaceuticals Inc.AX200G-CSFPreclinical	Phytopharm plc (LSE:PYM)	Myogane	Nonpeptide neurotrophic factor inducer	Phase I
Vasogen Inc. (TSX:VAS; NASDAQ:VSGN)VP025Anti-inflammatory compound that modulates cytokine levelsPhase ICeregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth factor-1PreclinicalRXi Pharmaceuticals Corp. (NASDAQ:RXII), subsidiary of CytRx Corp.Interfering RNA compoundRNAi compound inhibiting superoxide dismutase (SOD1)PreclinicalIsis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 33611Second-generation antisense inhibitor of SOD1PreclinicalNeuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABSNN0029VEGF proteinPreclinicalPreclinicalReata Pharmaceuticals Inc.AtX801G-CSFPreclinicalPreclinical	Trophos S.A.	TRO19622	Small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition pore	Phase I
Ceregene Inc.CERE-130Adeno-associated virus vectors carrying insulin-like growth factor-1PreclinicalRXi Pharmaceuticals Corp. (NASDAQ:RXII), subsidiary of CytRx Corp.Interfering RNA compoundRNAi compound inhibiting superoxide dismutase (SOD1)PreclinicalIsis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 33611Second-generation antisense inhibitor of SOD1PreclinicalNeuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABsNN0029VEGF proteinPreclinicalPreclinicalReata Pharmaceuticals Inc.AX200G-CSFPreclinicalPreclinical	Vasogen Inc. (TSX:VAS; NASDAQ:VSGN)	VP025	Anti-inflammatory compound that modulates cytokine levels	Phase I
RXi Pharmaceuticals Corp. (NASDAQ:RXII), subsidiary of CytRx Corp.Interfering RNA compoundRNAi compound inhibiting superoxide dismutase (SOD1)PreclinicalIsis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 333611Second-generation antisense inhibitor of SOD1PreclinicalNeuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABsNN0029VEGF proteinPreclinicalReata Pharmaceuticals Inc.RTA801SOD1 protein-folding stabilizerPreclinicalSygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	Ceregene Inc.	CERE-130	Adeno-associated virus vectors carrying insulin-like growth factor-1	Preclinical
Isis Pharmaceuticals Inc. (NASDAQ:ISIS)ISIS 333611Second-generation antisense inhibitor of SOD1PreclinicalNeuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABsNN0029VEGF proteinPreclinicalReata Pharmaceuticals Inc.RTA801SOD1 protein-folding stabilizerPreclinicalSygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	RXi Pharmaceuticals Corp. (NASDAQ:RXII), subsidiary of CytRx Corp.	Interfering RNA compound	RNAi compound inhibiting superoxide dismutase (SOD1)	Preclinical
Neuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)NNZ-4945Neural regeneration peptidePreclinicalNeuroNova ABsNN0029VEGF proteinPreclinicalReata Pharmaceuticals Inc.RTA801SOD1 protein-folding stabilizerPreclinicalSygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	Isis Pharmaceuticals Inc. (NASDAQ:ISIS)	ISIS 333611	Second-generation antisense inhibitor of SOD1	Preclinical
NeuroNova ABsNN0029VEGF proteinPreclinicalReata Pharmaceuticals Inc.RTA801SOD1 protein-folding stabilizerPreclinicalSygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	Neuren Pharmaceuticals Ltd. (ASX:NEU)/ Metabolic Pharmaceuticals Ltd. (ASX:MBP)	NNZ-4945	Neural regeneration peptide	Preclinical
Reata Pharmaceuticals Inc.RTA801SOD1 protein-folding stabilizerPreclinicalSygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	NeuroNova AB	sNN0029	VEGF protein	Preclinical
Sygnis Pharma AG (FSE:LIO)AX200G-CSFPreclinical	Reata Pharmaceuticals Inc.	RTA801	SOD1 protein-folding stabilizer	Preclinical
	Sygnis Pharma AG (FSE:LIO)	AX200	G-CSF	Preclinical

Table 1. Amyotropic lateral sclerosis pipeline. Selected compounds in development for ALS

<sup>A</sup>In January, the FDA placed a clinical hold on the trial and requested additional analyses of previously completed animal toxicology studies. <sup>B</sup>In March, the company reported that the compound missed the primary endpoint in a Phase II trial.

modulate the stability and folding of mutant SOD1, but it will keep an eye out for other potential targets such as TDP-43.

Reata's RTA801, a small molecule that stabilizes SOD1 in its native conformation, is in preclinical development to treat ALS.

Wigley suggested that combining knowledge of the hereditary and sporadic TDP-43 mutations identified by Shaw's group and the new assay reported by Lee's group could be useful in working out the disease mechanism. The TDP-43 mutations in the Shaw study were in a different part of the protein from the region identified by Lee, suggesting that multiple parts of the protein could contribute to ALS.

Very little is known about the normal biology of TDP-43, thus complicating efforts to directly target it. Initially identified as a protein that interacts with HIV DNA, TDP-43 is also involved in mRNA splicing. Rothstein suggested that at least some of the pathology of ALS could be due to the inability of mislocalized TDP-43 to participate in splicing; he cited clinical similarities between ALS and spinomuscular atrophy, which is caused by defects in an RNA-binding protein called survival of motor neuron 1.

Alternatively, ALS could result from the toxic effects of TDP-43 mislocalization. Lee's group found that expressing mutant TDP-43 in neurons caused normal TDP-43 to get stuck in the cytoplasm, forming ubiquitin-rich aggregates. Cytoplasmic inclusions full of ubiquitinated TDP-43 and other proteins are a common feature of neurodegenerative diseases such as Parkinson's disease.

Lee believes that TDP-43 aggregation also could underlie frontotemporal dementia, a form of cognitive impairment that sometimes accompanies ALS.

Rothstein said questions about the mechanism of TDP-43 toxicity and what therapeutic strategy to take will be easier to address once mouse models emerge. If knocking out TDP-43 causes ALS-like dis-

#### ease, or overexpression causes cytoplasmic aggregation and ALS-like pathology, the new protein could be a promising target for therapeutics.

"Once you have the mouse, you'll have a full platform," said Rothstein. For now, he said, it would be premature to "throw out the SOD model."

Even if TDP-43 proves to be primarily responsible for ALS, its ubiquitous expression and normally nuclear localization would make it a difficult drug target, according to Franz-Werner Haas, VP of operations at **Sygnis Pharma AG**.

Regardless of the specific disease mechanism, Haas said, Sygnis' AX200 recombinant G-CSF could have a broadly neuroprotective effect in ALS. The company plans to begin Phase I trials of AX200 in ALS this year.

Hopkins' Rothstein is a founder of **Ruxton Pharmaceuticals Inc.**, which aims to treat ALS by increasing glutamate transporter expression, which saves wear and tear on ALS-damaged neurons by lowering glutamate levels.

Other biotechs are also staying above the SOD1 and TDP-43 fray by targeting steps in nerve growth, angiogenesis and immune response that could ward off the degenerative effects of ALS in motor neurons. Compounds that target these processes are thought to act further downstream in the disease process than either SOD1 or TDP-43 and aim to reduce the severity of disease symptoms.

However, the track record for such drugs has thus far been poor, according to Aimee Kao, assistant adjunct professor of clinical neurology at the **University of California**, **San Francisco**. "By the time you see symptoms, the damage is too far gone" for nerve-preserving therapies to have much effect, she said.

Therapies aimed at a suspected autoimmune response in ALS have also been unsuccessful. For example, **Teva Pharmaceutical Industries Ltd.** announced this month that a Phase II trial of Copaxone glatiramer acetate for ALS had failed. Copaxone, an immunomodulatory amino acid polymer, is approved to treat multiple sclerosis.

However, the Zlokovic report in *Nature Neuroscience* bolsters the case for **Sangamo BioSciences Inc.**'s SB-509, a transcriptional activator of VEGF-A, which stimulates blood vessel growth. The study showed that the brains of SOD1 mutant mice have shorter capillaries and lower blood flow than wild-type controls.

Last year, Sangamo reported that SB-509 improved nerve conduction and sensation compared with placebo in a Phase Ib trial

"We want to bridge the gap between target identification, which academia does very well, and the preclinical stuff that generates lead compounds, which is usually done in biotech or pharma." – Virginia Lee,

University of Pennsylvania School of Medicine

## **COVER STORY**

in diabetic neuropathy. Spokesperson Liz Wolffe told *SciBX* that the company plans to begin a Phase II trial of SB-509 for ALS this year.

Meanwhile, Lee told *SciBX* that her group is forging ahead with a high-throughput screening project through the University of Pennsylvania's Marian S. Ware Alzheimer Program. The group is looking for compounds that modulate TDP-43 localization or activity.

"We want to bridge the gap between target identification, which academia does very well,

and the preclinical stuff that generates lead compounds, which is usually done in biotech or pharma," said Lee. "The new model is to bypass the biotech company and do all of the preclinical, toxicity and pharmacodynamics and then negotiate directly" with pharma companies interested in the clinical development of lead compounds.

#### REFERENCES

- 1. Miller, R.G. et al. Cochrane Database Syst. Rev. 1, CD001447; published online Jan. 24, 2007; doi:10.1002/14651858.CD001447.pub2
- Sreedharan, J. *et al. Science*; published online Feb. 27, 2008; doi:10.1126/science.1154584
  Contact: Christopher E. Shaw, Department of Clinical Neurosciences, King's College London, U.K. e-mail: chris.shaw@iop.kcl.ac.uk
- Winton, M.J. et al. J. Biol. Chem.; published online Feb. 27, 2008; doi:10.1074/jbc.M800342220
  Contact: Virginia M.-Y. Lee, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pa. e-mail: vmylee@mail.med.upenn.edu
- 4. Neumann, M. et al. Science 314, 130-133 (2006)
- Zhong Z. et al. Nat. Neurosci.; published online Mar. 16, 2008; doi:10.1038/nn2073
  Contact: Berislav Zlokovic, Center for Neurodegenerative and Vascular Brain Disorders and Departments of Neurosurgery and Neurology, University of Rochester Medical Center, Rochester, N.Y. e-mail: berislav\_zlokovic@urmc.rochester.edu
- Gitcho, M.A. et al. Ann. Neurol.; published online Feb. 20, 2008; doi:10.1002/ana.21344

#### COMPANIES AND INSTITUTIONS MENTIONED

Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Johns Hopkins University, Baltimore, Md. King's College London, London, U.K. Reata Pharmaceuticals Inc., Dallas, Texas Ruxton Pharmaceuticals Inc., Lutherville, Md. Sangamo BioSciences Inc. (NASDAQ:SGMO), Richmond, Calif. sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France Sygnis Pharma AG (FSE:LIO), Heidelberg, Germany Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), Jerusalem, Israel University of California, San Francisco, San Francisco, Calif. University of Pennsylvania School of Medicine, Philadelphia, Pa. University of Rochester Medical Center, Rochester, N.Y.